Valeant was once considered a runaway success story, and one that upended the pharmaceutical sector. A series of crises engulfed the company in recent months, slashing nearly two thirds off its market valuation and forcing the company to tear up its forecasts for 2016. Correspondent David Crow explains. Read the full story at Music: "Brand New Record!" by Steve Combs

iTunes Stitcher audioBoom SoundCloud Overcast RSS

Copyright The Financial Times Limited 2017. All rights reserved.

Follow the topics related to this show

Comments have not been enabled for this podcast.